Andreessen Horowitz, Google Ventures, Verily, and others have invested $77 million in Freenome, which uses machine learning to pinpoint immune-system responses that may indicate the presence of cancer. Freenome’s most prominent rival, Grail—which plans to harness next-generation gene sequencing to directly measure cancerous genomic alterations in the blood—raised $1.2 billion last year from ARCH Venture Partners. Both companies are racing to make the first DNA-detecting blood test to reveal disease in its earliest stages. It’s the holy—well, you know—of cancer care.
If this scientific sprint is giving you Theranos flashbacks, it should. Critics believe that even with the aid of low-cost genetic sequencing and high-powered algorithms, liquid biopsy detection is still years away from